Media Contact: [email protected] 

Black Women's Health Imperative Praises FDA Decision on Abortion Pill

Published Wednesday, March 30, 2016

Washington, D.C. – The Black Women’s Health Imperative applauds the Food and Drug Administration’s decision to change the label for the abortion pill Mifepristone (Mifeprex). This move increases access and availability to a safe and effective method of abortion and, now that providers can prescribe a lower dose, this makes medication abortion a safer option for women. 

“The FDA is to be commended for reviewing the evidence and updating the Mifepristone usage label. Women across the U.S., especially Black women and low-income women who have historically faced barriers to abortion care, will now have many of those barriers eliminated,” said Linda Goler Blount, president and CEO of the Black Women's Health Imperative. 

The Black Women’s Health Imperative has long fought for women to have access to safe abortion care. Research shows unintended pregnancies and resulting births are among the leading contributors to poverty.  

“With Mifepristone, women are in greater charge of their reproductive health and can have children if and when they are ready," said Blount.



About the Black Women’s Health Imperative
The Black Women’s Health Imperative is the only national organization dedicated to improving the health and wellness of the nation’s 21 million Black women and girls — physically, emotionally and financially.  We identify the most pressing health issues and invest in the best of the best strategies, partners and organizations that share our goal: ensuring Black women live longer, healthier more prosperous lives.